Oxford BioTherapeutics Appoints Dr Keith E Wilson As Chief Scientific Officer
OXFORD, UK and SAN JOSE, CA – 18 June 2014 – Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today the appointment of Dr Keith E Wilson as Chief Scientific Officer. Dr Wilson joins from AbbVie where he was the company's Global Leader for Antibody Drug Conjugates.
Dr Keith E Wilson brings to Oxford BioTherapeutics over 20 years' experience of life sciences research and development, specializing in oncology and immunology. He has extensive experience of developing and executing novel discovery, clinical and portfolio strategies, as well as providing executive-level support for corporate and business development activities. In his most recent role, he was Director, Biologics Technology and Global Leader, Antibody Drug Conjugates at AbbVie, where he was responsible for corporate ADC strategy with multiple programs in pre-clinical and clinical development, as well as leading a large multi-functional discovery team. Previously, he was Senior Director of Research at Facet Biotech, prior to which he was Director, Pipeline Strategy / Early Discovery and Computational Biology at PDL BioPharma. He also held positions of increasing seniority at EOS Biotechnology, where he began his industry career as a scientist. Dr Wilson holds a PhD in Biochemistry and Molecular Biology from the Oregon Health Sciences University, and conducted post-doctoral research at Stanford University.
"I am delighted that Keith has chosen to join Oxford BioTherapeutics, where his world-class experience in leading ADC development programs will prove invaluable as we advance our pipeline into the clinic," said Dr Christian Rohlff, Oxford BioTherapeutics' CEO.
Commenting on his appointment, Dr Keith E Wilson, Oxford BioTherapeutics' CSO, said, "I am highly impressed by the progress Oxford BioTherapeutics has made with its ADC programs, both scientifically and with the range and quality of the company's technology collaborations and development partnerships. I look forward to helping the team continue this success as the company progresses its candidates into clinical development."
- Ends -
About Oxford BioTherapeutics
Oxford BioTherapeutics is developing a range of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company's ADCs are based on its proprietary OGAP® targeting platform, and incorporate novel antibody and cancer toxin technologies accessed from leading companies in the field. Oxford BioTherapeutics' network of collaborations provides a unique range of complementary ADC technologies, allowing the company to select the optimal combination for each target identified by its OGAP® system. OGAP® incorporates one of the world's largest proprietary proteomic databases, with data on over 5,000 cancer cell proteins providing unique, highly-qualified oncology targets selected for optimal ADC activity. In 2012, Oxford BioTherapeutics entered a strategic agreement to accelerate the development of its ADCs, with partner Menarini providing clinical and manufacturing expertise, investment of up to $1 billion and potential milestone and royalty payments, in exchange for commercial rights in Europe, Asia and Latin America. Oxford BioTherapeutics retains the rights in the US and Japan.
Dr Christian Rohlff
+44 (0) 1235 861770
David Dible / Sita Shah
Citigate Dewe Rogerson
+44 (0) 207 638 9571